Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan

Haemophilia

Volumn 15, Issue 1, 2009, Pages 78-82

  Taki, M ^a   Shirahata, A ^b  

^a ST MARIANNA UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Age; Haemophilia; Japanese survey; Prophylaxis; Severity

Indexed keywords

BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANXIETY; ARTICLE; CAREGIVER; CHEMOPROPHYLAXIS; DISEASE SEVERITY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; JAPAN; NURSE; PERIPHERAL VEIN; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SUBSTITUTION THERAPY;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FACTOR IX; FACTOR VIII; HEALTH CARE SURVEYS; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFANT; JAPAN; MALE; PHYSICIAN'S PRACTICE PATTERNS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 63049124187     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01823.x     Document Type: Article

References (14)

1. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years'experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
2. Van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
3. Royal S, Schramm W, Berntorp E et al. Quality-of-Life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
4. Morado M, Villar A, Jimenez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: Experience in one center. Haemophilia 2005; 11: 79-83.
5. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
6. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
7. MASAC. Medical and Scientific Advisory Council (MASAC) Recommendations Concerning Prophylaxis. MASAC Medical Bulletin No. 179. NY: NHF, 1994.
8. Manco-Johnson M, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
9. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy -global progress towards optimal care. Haemophilia 2006; 12: 75-81.
10. Taki M. Mini symposium at the hemophilia standardization subcommittee: present situation of the prophylaxis for hemophilia. Jpn J Thromb Haemost 2002; 13: 109-13.
11. Yazaki M, Mizutani K, Ito Y. Experiences of prophylaxis replacement therapy for hemophilia. Jpn Pediatr Hematol 2006; 20: 22-5.
12. Taki M, Ohi C, Yamashita A. Six years's experience of regular continuous prophylactic infusion of clotting factor concentrates in infants and young children with severe hemophilia A and B in Japan. J Thromb Haemost 2005; 3 (Suppl.1): P0235.
13. Okimoto Y, Sunami S, Komori I et al. Experience of prohilaxis from infant age of hemopilia. Jpn J Clin Hematol 2004; 45: 948.
14. Japanese Foundation for AIDS Prevention. National Survey on Blood Coagulation Abnormality, 2003 Report. Tokyo: Japanese Foundation for AIDS Prevention, 2002.